Product Description
JDB175 is a highly selective second-generation oral inhibitor of Bruton's tyrosine kinase (BTK). BTK is a key protein molecule in the B cell receptor pathway and is involved in the proliferation, transport, chemotaxis and activation of B cells. Adhesion is widely expressed in different types of hematological malignancies, and inhibition of its activity can produce significant antitumor effects. Preclinical tests have shown that JDB175 has good BTK selective inhibition compared with similar drugs, and has good safety and tolerance, and has good anticancer activity in DLBCL. (Sourced from: https://www.vbdata.cn/53598)
Mechanisms of Action: Btk Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Shanghai Jiabao Yaoyin Pharmaceutical Technology Co., Ltd.
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Diffuse Large B-Cell Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| CTR20232048 | P1 |
Recruiting |
Diffuse Large B-Cell Lymphoma |
None |
2025-05-17 |
Patient Enrollment|Start Date|Treatments |
Recent News Events
Date |
Type |
Title |
|---|